Developer docs
API playgroundTry for free, no card

Search company profiles

Rallybio

Full company profile

uuid0000afr

Namestring
Rallybio
Legal namestring
Rallybio Corporation
Websiteurl
rallybio.com
Company typeenum
Public
Founded yearint
2017
Descriptiontext

Rallybio is a clinical-stage biopharmaceutical company developing therapeutics for rare and severe diseases, with therapeutic focus on complement dysregulation and hematology. Founded in 2017 and headquartered in New Haven, Connecticut, the company went public on NASDAQ in 2021 under the ticker RLYB and employs between 11 and 50 people. Its pipeline comprises four core programs: RLYB116, a once-weekly subcutaneous C5 inhibitor built on a licensed Affibody-Albumod fusion protein platform targeting paroxysmal nocturnal hemoglobinuria, generalized myasthenia gravis, and antiphospholipid syndrome; RLYB114, a PEGylated C5 Affibody for intravitreal treatment of complement-driven ophthalmic disease; RLYB332, an anti-matriptase-2 monoclonal antibody for iron overload and severe anemias; and RLYB212, an anti-HPA-1a antibody for prevention of fetal and neonatal alloimmune thrombocytopenia, co-developed with Johnson & Johnson.

Rallybio is pre-revenue with no commercialized products; reported Q3 2025 operating revenue was $0.22 million, supplemented by a one-time $20 million gain on the sale of its REV102 ENPP1 inhibitor program to Recursion Pharmaceuticals. Revenue mechanics, when products reach market, are expected to come from specialty pharmacy and hospital purchasing channels for rare-disease biologics, with potential global commercialization through a Big Pharma partner. Capital sources to date include a $145 million Series B in 2020 led by Pivotal bioVenture Partners, a $50 million public offering in November 2022, the J&J collaboration ($7 million+ in cash and equity), and the $215 million private placement backing the pending Avenzo Therapeutics merger.

Strategically, Rallybio has executed a defensive pivot: it divested REV102 in July 2025, implemented a 1-for-8 reverse stock split in February 2026 to maintain Nasdaq compliance, received a $50 million termination fee when its Candid Therapeutics reverse merger collapsed in May 2026, and announced a definitive merger with oncology developer Avenzo Therapeutics in June 2026 that would leave pre-merger Avenzo equityholders owning approximately 97.2% of the combined company under the ticker AVZO.

Short descriptiontext

Rallybio is a clinical-stage biopharmaceutical company developing complement and hematology therapeutics for rare diseases, with a pipeline led by subcutaneous C5 inhibitor RLYB116 and anti-matriptaste-2 antibody RLYB332. It is pre-revenue and is pursuing a reverse merger with Avenzo Therapeutics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew Haven, United States
HQ citystring
New Haven
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease therapeutics, complement inhibitors, biopharmaceutical development, monoclonal antibody therapies, hematology drug development
Industry1 code
PRIMARYHLAAAFAB
Microbiome-Derived Metabolite Therapeutics (postbiotics)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pre-revenue clinical stage company with no commercialized products. Revenue expected from future sales of rare disease therapeutics upon regulatory approval.

rallybio.com
2Partnership and Collaboration Revenue
TypeLicensing Royalties
Description

Rallybio receives funding and equity investments from strategic partners including Johnson & Johnson for development of RLYB212 for FNAIT.

biospace.com
3Milestone Payments
TypeLicensing Royalties
Description

Rallybio earns milestone payments tied to clinical development and regulatory achievements, including upfront payments and development-based payments from collaborations.

fiercebiotech.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Rallybio is a clinical-stage biopharmaceutical company developing a pipeline of novel therapeutics for severe and rare diseases, with primary focus on complement dysregulation and hematology. The company's core pipeline includes RLYB116 (subcutaneous C5 inhibitor for complement-mediated diseases such as PNH, gMG, and APS), RLYB332 (anti-matriptase-2 antibody for iron overload diseases), RLYB114 (intravitreal C5 inhibitor for ophthalmic diseases), and RLYB212 (monoclonal antibody for FNAIT prevention). Rallybio has no commercialized products and is pre-revenue, relying on partnership funding and milestone payments.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • RLYB116 demonstrated complete and sustained inhibition of terminal complement at 300mg dose in healthy volunteers with favorable tolerability
+2 more records
Product overview1 text field

Rallybio is a clinical-stage biotech company developing a pipeline of novel therapeutics for severe and rare diseases, with focus areas in complement dysregulation and hematology. The core portfolio includes RLYB116 (subcutaneous C5 inhibitor for complement-mediated diseases including PNH, gMG, and APS), RLYB332 (matriptase-2 inhibitor for iron overload diseases), RLYB114 (C5 inhibitor for ophthalmic diseases), and RLYB212 (monoclonal antibody for FNAIT prevention). The company also had a partnership with AbCellera for an undisclosed metabolic disease program. Rallybio sold its REV102 ENPP1 inhibitor program to Recursion Pharmaceuticals.

Product and service4 records
1RLYB116
CategoryComplement-mediated disease therapeutics
Description

A novel, once-weekly, small volume, subcutaneously injected C5 inhibitor (antibody mimetic fusion protein) designed to inhibit Complement Factor 5 for complement-mediated diseases including paroxysmal nocturnal hemoglobinuria (PNH), generalized myasthenia gravis (gMG), and antiphospholipid syndrome (APS).

2RLYB332
CategoryHematology and iron overload therapeutics
Description

A long-acting monoclonal anti-matriptase-2 antibody designed to inhibit MTP-2, thereby increasing hepcidin levels to treat diseases of iron overload and severe anemias including hereditary hemochromatosis, polycythemia vera, myelodysplastic syndrome, beta thalassemia, and sickle cell anemia.

3RLYB114
CategoryOphthalmic complement therapeutics
Description

A C5-targeted Affibody molecule conjugated to polyethylene glycol (PEG) for complement-driven ophthalmic diseases, administered via intravitreal injection for conditions such as age-related macular degeneration (AMD).

4RLYB212
CategoryFNAIT prevention therapeutics
Description

A monoclonal antibody therapeutic aimed at pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia (FNAIT), designed to prevent the condition which is a rare but potentially fatal disease affecting fetuses and newborns.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-01
Description

Rallybio announced definitive merger agreement with Avenzo Therapeutics, a cancer drug developer. Combined company will operate as Avenzo Therapeutics and trade on Nasdaq under ticker AVZO. Concurrent $215 million private placement financing. Pre-closing Avenzo equityholders expected to own approximately 97.2% of merged entity. Deal expected to close Q4 2026.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-02
Description

Rallybio announced merger agreement with Candid Therapeutics in a reverse merger transaction. Candid raised over $505 million in concurrent private financing. Combined company expected to have approximately $700 million cash at closing, operating as Candid Therapeutics with ticker CDRX. Deal expected to close mid-2026. Rallybio shareholders to own approximately 3.65% of combined entity.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-07-08
Description

Rallybio sold its interest in the REV102 ENPP1 inhibitor program to Recursion Pharmaceuticals for up to $25 million including $7.5 million upfront equity payment plus near-term milestones. Rallybio receives low single-digit royalties on future net sales.

Strategic tierCoreTypeTechnology or Integration
Description

Rallybio has licensed Affibody technology for development of C5 inhibitors including RLYB116. The Affibody molecule provides high affinity binding to complement factor C5 for terminal complement inhibition.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership with AbCellera for development of an undisclosed metabolic disease program. AbCellera provides antibody discovery technology.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Acquired by AstraZeneca for $39B in 2021, Alexion is the dominant player in complement-mediated disease therapeutics (Soliris, Ultomiris). Rallybio's RLYB116 C5 inhibitor is directly aimed at Alexion's PNH/gMG franchise, and Rallybio's founding team (Uden, Mackay) came from Alexion.

TypeDirect peer
Description

Clinical-stage complement therapeutics company with approved C3 inhibitors (Empaveli, Syfovre) targeting PNH and geographic atrophy. Apellis competes head-to-head with Rallybio's RLYB116 in complement dysregulation and represents the most relevant next-generation complement peer.

TypeBroad incumbent
Description

Established rare disease biopharma with a portfolio of approved enzyme replacement therapies and gene therapies. BioMarin is comparable to Rallybio in rare disease focus and commercial infrastructure readiness, though at vastly greater scale.

TypeBroad incumbent
Description

Major rare disease biopharma with multiple approved CF therapies and an emerging hematology/iron-overload program. Comparable in clinical-stage hematology focus (including programs targeting iron dysregulation analogous to Rallybio's RLYB332).

TypeDirect peer
Description

Commercial-stage biotech with FcRn antagonist Vyvgart (approved for gMG, expanding indications) — a direct competitor to Rallybio's complement-mediated gMG approach. argenx represents a parallel path to addressing complement/autoimmune-driven rare diseases.

TypeBroad incumbent
Description

Specialty rare disease biopharma with hematology and immunology franchises including complement therapies. Sobi's commercial rare-disease infrastructure and product portfolio are comparable in therapeutic focus to Rallybio's pipeline.

TypeBroad incumbent
Description

Global biopharma with significant rare disease, hematology, and plasma-derived therapy franchises. Takeda's rare hematology and immunology portfolio overlaps with Rallybio's RLYB116 and RLYB332 indications.

TypeEmerging player
Description

Antisense oligonucleotide platform company developing therapies for rare and serious diseases including complement-mediated disorders. Ionis represents an alternative modality (RNA-based) addressing overlapping complement disease biology.

TypeEmerging player
Description

RNAi therapeutics company with rare disease focus including hematology programs (e.g., Givosiran for AHP). Alnylam's rare disease development expertise and platform-driven pipeline parallel Rallybio's Affibody-platform model.

TypeOthers
Description

Tech-enabled drug discovery company that acquired Rallybio's REV102 ENPP1 inhibitor program for $25M in 2025. Recursion is a transaction counterparty (not a competitor) but exemplifies adjacent platforms operating in similar rare disease discovery space.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Rallybio

Biopharmaceuticalsrallybio.com

Rallybio is a clinical-stage biopharmaceutical company developing complement and hematology therapeutics for rare diseases, with a pipeline led by subcutaneous C5 inhibitor RLYB116 and anti-matriptaste-2 antibody RLYB332. It is pre-revenue and is pursuing a reverse merger with Avenzo Therapeutics.

What Rallybio does

Rallybio is a clinical-stage biopharmaceutical company developing therapeutics for rare and severe diseases, with therapeutic focus on complement dysregulation and hematology. Founded in 2017 and headquartered in New Haven, Connecticut, the company went public on NASDAQ in 2021 under the ticker RLYB and employs between 11 and 50 people. Its pipeline comprises four core programs: RLYB116, a once-weekly subcutaneous C5 inhibitor built on a licensed Affibody-Albumod fusion protein platform targeting paroxysmal nocturnal hemoglobinuria, generalized myasthenia gravis, and antiphospholipid syndrome; RLYB114, a PEGylated C5 Affibody for intravitreal treatment of complement-driven ophthalmic disease; RLYB332, an anti-matriptase-2 monoclonal antibody for iron overload and severe anemias; and RLYB212, an anti-HPA-1a antibody for prevention of fetal and neonatal alloimmune thrombocytopenia, co-developed with Johnson & Johnson.

Rallybio is pre-revenue with no commercialized products; reported Q3 2025 operating revenue was $0.22 million, supplemented by a one-time $20 million gain on the sale of its REV102 ENPP1 inhibitor program to Recursion Pharmaceuticals. Revenue mechanics, when products reach market, are expected to come from specialty pharmacy and hospital purchasing channels for rare-disease biologics, with potential global commercialization through a Big Pharma partner. Capital sources to date include a $145 million Series B in 2020 led by Pivotal bioVenture Partners, a $50 million public offering in November 2022, the J&J collaboration ($7 million+ in cash and equity), and the $215 million private placement backing the pending Avenzo Therapeutics merger.

Strategically, Rallybio has executed a defensive pivot: it divested REV102 in July 2025, implemented a 1-for-8 reverse stock split in February 2026 to maintain Nasdaq compliance, received a $50 million termination fee when its Candid Therapeutics reverse merger collapsed in May 2026, and announced a definitive merger with oncology developer Avenzo Therapeutics in June 2026 that would leave pre-merger Avenzo equityholders owning approximately 97.2% of the combined company under the ticker AVZO.

Rallybio firmographics

Firmographics
Name
Rallybio
Legal name
Rallybio Corporation
Website
https://rallybio.com
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Rallybio is a clinical-stage biopharmaceutical company developing complement and hematology therapeutics for rare diseases, with a pipeline led by subcutaneous C5 inhibitor RLYB116 and anti-matriptaste-2 antibody RLYB332. It is pre-revenue and is pursuing a reverse merger with Avenzo Therapeutics.
Ownership category
akta.pro rank

Rallybio industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAFAB
Microbiome-Derived Metabolite Therapeutics (postbiotics)

Keywords

  • Rare disease therapeutics
  • Complement inhibitors
  • Biopharmaceutical development
  • Monoclonal antibody therapies
  • Hematology drug development

Where Rallybio is headquartered

Location

Headquarters

HQ city
New Haven
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Rallybio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Pharmaceutical Product Sales: Pre-revenue clinical stage company with no commercialized products. Revenue expected from future sales of rare disease therapeutics upon regulatory approval.
  2. Partnership and Collaboration Revenue: Rallybio receives funding and equity investments from strategic partners including Johnson & Johnson for development of RLYB212 for FNAIT.
  3. Milestone Payments: Rallybio earns milestone payments tied to clinical development and regulatory achievements, including upfront payments and development-based payments from collaborations.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Rallybio product offering

Product offering

Core offering

Rallybio is a clinical-stage biopharmaceutical company developing a pipeline of novel therapeutics for severe and rare diseases, with primary focus on complement dysregulation and hematology. The company's core pipeline includes RLYB116 (subcutaneous C5 inhibitor for complement-mediated diseases such as PNH, gMG, and APS), RLYB332 (anti-matriptase-2 antibody for iron overload diseases), RLYB114 (intravitreal C5 inhibitor for ophthalmic diseases), and RLYB212 (monoclonal antibody for FNAIT prevention). Rallybio has no commercialized products and is pre-revenue, relying on partnership funding and milestone payments.

Product overview

Rallybio is a clinical-stage biotech company developing a pipeline of novel therapeutics for severe and rare diseases, with focus areas in complement dysregulation and hematology. The core portfolio includes RLYB116 (subcutaneous C5 inhibitor for complement-mediated diseases including PNH, gMG, and APS), RLYB332 (matriptase-2 inhibitor for iron overload diseases), RLYB114 (C5 inhibitor for ophthalmic diseases), and RLYB212 (monoclonal antibody for FNAIT prevention). The company also had a partnership with AbCellera for an undisclosed metabolic disease program. Rallybio sold its REV102 ENPP1 inhibitor program to Recursion Pharmaceuticals.

Differentiator

Problem solved

Functional benefit

Products and services

  • RLYB116 A novel, once-weekly, small volume, subcutaneously injected C5 inhibitor (antibody mimetic fusion protein) designed to inhibit Complement Factor 5 for complement-mediated diseases including paroxysmal nocturnal hemoglobinuria (PNH), generalized myasthenia gravis (gMG), and antiphospholipid syndrome (APS).
  • RLYB332 A long-acting monoclonal anti-matriptase-2 antibody designed to inhibit MTP-2, thereby increasing hepcidin levels to treat diseases of iron overload and severe anemias including hereditary hemochromatosis, polycythemia vera, myelodysplastic syndrome, beta thalassemia, and sickle cell anemia.
  • RLYB114 A C5-targeted Affibody molecule conjugated to polyethylene glycol (PEG) for complement-driven ophthalmic diseases, administered via intravitreal injection for conditions such as age-related macular degeneration (AMD).
  • RLYB212 A monoclonal antibody therapeutic aimed at pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia (FNAIT), designed to prevent the condition which is a rare but potentially fatal disease affecting fetuses and newborns.

Quantifiable outcome

  • RLYB116 demonstrated complete and sustained inhibition of terminal complement at 300mg dose in healthy volunteers with favorable tolerability
  • +2 more outcomes

Companies that use Rallybio

Customer profile

Segments4 records

Ideal customer profiles2 records

Rallybio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Rallybio partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Avenzo TherapeuticscoreStrategic or Co-development Partner · 1 June 2026Rallybio announced definitive merger agreement with Avenzo Therapeutics, a cancer drug developer. Combined company will operate as Avenzo Therapeutics and trade on Nasdaq under ticker AVZO. Concurrent $215 million private placement financing. Pre-closing Avenzo equityholders expected to own approximately 97.2% of merged entity. Deal expected to close Q4 2026.
  • Candid TherapeuticscoreStrategic or Co-development Partner · 2 March 2026Rallybio announced merger agreement with Candid Therapeutics in a reverse merger transaction. Candid raised over $505 million in concurrent private financing. Combined company expected to have approximately $700 million cash at closing, operating as Candid Therapeutics with ticker CDRX. Deal expected to close mid-2026. Rallybio shareholders to own approximately 3.65% of combined entity.
  • Recursion PharmaceuticalsminorStrategic or Co-development Partner · 8 July 2025Rallybio sold its interest in the REV102 ENPP1 inhibitor program to Recursion Pharmaceuticals for up to $25 million including $7.5 million upfront equity payment plus near-term milestones. Rallybio receives low single-digit royalties on future net sales.
  • AffibodycoreTechnology or IntegrationRallybio has licensed Affibody technology for development of C5 inhibitors including RLYB116. The Affibody molecule provides high affinity binding to complement factor C5 for terminal complement inhibition.
  • AbCelleraminorStrategic or Co-development PartnerPartnership with AbCellera for development of an undisclosed metabolic disease program. AbCellera provides antibody discovery technology.

Scale indicators11 records

Recent moves6 records

Expansion highlights5 records

Rallybio competitors and assessment

Company assessment

Broad incumbents

  • Alexion (AstraZeneca Rare Disease): Acquired by AstraZeneca for $39B in 2021, Alexion is the dominant player in complement-mediated disease therapeutics (Soliris, Ultomiris). Rallybio's RLYB116 C5 inhibitor is directly aimed at Alexion's PNH/gMG franchise, and Rallybio's founding team (Uden, Mackay) came from Alexion.
  • BioMarin Pharmaceutical: Established rare disease biopharma with a portfolio of approved enzyme replacement therapies and gene therapies. BioMarin is comparable to Rallybio in rare disease focus and commercial infrastructure readiness, though at vastly greater scale.
  • Vertex Pharmaceuticals: Major rare disease biopharma with multiple approved CF therapies and an emerging hematology/iron-overload program. Comparable in clinical-stage hematology focus (including programs targeting iron dysregulation analogous to Rallybio's RLYB332).
  • Swedish Orphan Biovitrum (Sobi): Specialty rare disease biopharma with hematology and immunology franchises including complement therapies. Sobi's commercial rare-disease infrastructure and product portfolio are comparable in therapeutic focus to Rallybio's pipeline.
  • Takeda Pharmaceutical: Global biopharma with significant rare disease, hematology, and plasma-derived therapy franchises. Takeda's rare hematology and immunology portfolio overlaps with Rallybio's RLYB116 and RLYB332 indications.

Direct peers

  • Apellis Pharmaceuticals: Clinical-stage complement therapeutics company with approved C3 inhibitors (Empaveli, Syfovre) targeting PNH and geographic atrophy. Apellis competes head-to-head with Rallybio's RLYB116 in complement dysregulation and represents the most relevant next-generation complement peer.
  • argenx: Commercial-stage biotech with FcRn antagonist Vyvgart (approved for gMG, expanding indications) — a direct competitor to Rallybio's complement-mediated gMG approach. argenx represents a parallel path to addressing complement/autoimmune-driven rare diseases.

Emerging players

  • Ionis Pharmaceuticals: Antisense oligonucleotide platform company developing therapies for rare and serious diseases including complement-mediated disorders. Ionis represents an alternative modality (RNA-based) addressing overlapping complement disease biology.
  • Alnylam Pharmaceuticals: RNAi therapeutics company with rare disease focus including hematology programs (e.g., Givosiran for AHP). Alnylam's rare disease development expertise and platform-driven pipeline parallel Rallybio's Affibody-platform model.

Others

  • Recursion Pharmaceuticals: Tech-enabled drug discovery company that acquired Rallybio's REV102 ENPP1 inhibitor program for $25M in 2025. Recursion is a transaction counterparty (not a competitor) but exemplifies adjacent platforms operating in similar rare disease discovery space.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Rallybio social profiles

Digital presence

Rallybio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Rallybio leadership team

Management profile

Number of profiles

Profiles5 records

Rallybio funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Rallybio M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rallybio

What does Rallybio do?

Rallybio is a clinical-stage biopharmaceutical company developing a pipeline of novel therapeutics for severe and rare diseases, with primary focus on complement dysregulation and hematology. The company's core pipeline includes RLYB116 (subcutaneous C5 inhibitor for complement-mediated diseases such as PNH, gMG, and APS), RLYB332 (anti-matriptase-2 antibody for iron overload diseases), RLYB114 (intravitreal C5 inhibitor for ophthalmic diseases), and RLYB212 (monoclonal antibody for FNAIT prevention). Rallybio has no commercialized products and is pre-revenue, relying on partnership funding and milestone payments.

Is Rallybio a public or private company?

Rallybio is a public company. It is classified as public and is currently operating.

When was Rallybio founded?

Rallybio was founded in 2017. It employs 11 to 50 people.

Where is Rallybio based?

Rallybio is headquartered in New Haven, United States, in the North America region.

How does Rallybio make money?

Three revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are partnership and Collaboration Revenue and milestone Payments.

Who are Rallybio's main competitors?

Broad incumbents on record are Alexion (AstraZeneca Rare Disease), BioMarin Pharmaceutical, Vertex Pharmaceuticals, Swedish Orphan Biovitrum (Sobi) and Takeda Pharmaceutical. Direct peers are Apellis Pharmaceuticals and argenx. Emerging players are Ionis Pharmaceuticals and Alnylam Pharmaceuticals. Recursion Pharmaceuticals is listed as an others.

Does Rallybio have an API?

No public API is recorded for Rallybio.

What industry is Rallybio in?

Rallybio's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAFAB, Microbiome-Derived Metabolite Therapeutics (postbiotics). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewRallybio Corporation (RLYB) Sets Reverse Split for 4:01 P.M. ET Nov. 20Rallybio corrected the effective time of its one-for-two reverse stock split to 4:01 p.m. ET on Nov. 20, 2026, with post-split trading expected to begin Nov. 23. The correction adjusts the previously announced timing, not the split ratio.Dealroom.coRallybio to become oncology player Avenzo, backed by $215M placementRallybio will merge with Avenzo Therapeutics and trade as Avenzo on the Nasdaq Capital Market under the symbol AVZO. The deal is backed by a $215 million private placement and a $83.6 million cash distribution to Rallybio holders. A one-for-two reverse split will take effect on November 20, 2026, before the merger closes.TradingViewRallybio Postpones Merger Closing Pending Listing ApprovalsRallybio postponed its merger closing, previously set for November 6, 2026, because certain post-closing share-listing conditions remain unmet. The company did not deposit funds for the cash distribution with Computershare on November 5, and the payment and ex-dividend dates may be delayed. Rallybio said it will provide further updates as appropriate.MarketBeatRallybio (RLYB) Set to Post Quarterly Earnings on ThursdayRallybio is set to release Q3 2026 earnings before market open on Thursday, November 5th, with analysts expecting a loss of $1.44 per share. The company previously reported a loss of $0.48 per share, beating the consensus by $0.96. It also announced a special dividend of $13.56 per share payable on November 13th.Ticker ReportRallybio Corporation (NASDAQ:RLYB) Shareholders to Collect $13.56 Special DividendRallybio declared a special dividend of $13.56 per share, payable to shareholders of record on November 5th on November 13th. The stock fell 4.3% to $15.93, and the company reported a quarterly loss of $0.48 per share.FinancialContent Business PageRallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYBLaw firm Kahn Swick & Foti, LLC is investigating the proposed merger of Rallybio Corporation and Avenzo Therapeutics. The firm seeks to determine whether the merger is fair to Rallybio shareholders, noting that pre-transaction Rallybio equityholders would own approximately 2.8% of the combined company.Defense WorldHead to Head Analysis: Rallybio (NASDAQ:RLYB) versus NewAmsterdam Pharma (NASDAQ:NAMS)NewAmsterdam Pharma and Rallybio are compared on analyst ratings, valuation, and institutional ownership. NewAmsterdam has a stronger consensus rating, a $49 target price implying 127% upside, and beats Rallybio on 11 of 15 factors. Rallybio has lower revenue but higher earnings per share.American Banking and Market NewsHead to Head Analysis: Alector (NASDAQ:ALEC) & Rallybio (NASDAQ:RLYB)Alector beats Rallybio on 8 of 14 factors, including higher revenue and a stronger analyst consensus. Alector's consensus price target of $3.40 implies a 63.46% upside, while Rallybio trades at a lower P/E but lower revenue. Alector is favored by analysts.Markets DailyFinancial Analysis: NewAmsterdam Pharma (NASDAQ:NAMS) versus Rallybio (NASDAQ:RLYB)NewAmsterdam Pharma and Rallybio are compared on profitability, valuation, and analyst ratings. NewAmsterdam has a consensus target price of $49.00, implying 130.48% upside, and beats Rallybio on 11 of 15 factors. Analysts favor NewAmsterdam due to its stronger rating and higher upside.GurufocusAre DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their ShareholHalper Sadeh LLC, an investor rights law firm, announced investigations into four proposed mergers for potential violations of federal securities laws and breaches of fiduciary duties to shareholders. The mergers under scrutiny are Destination XL Group's acquisition by FBB Holdings I, Standard BioTools' merger with Treeline Biosciences, First Hawaiian's merger with TriCo Bancshares, and Rallybio's merger with Candid Therapeutics. The law firm stated it may seek increased consideration, additional disclosures, or other relief on behalf of shareholders.